Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the Big Data for Better Outcomes Programme (BD4BO), the overarching goal of PIONEER is to provide high-quality evidence on prostate cancer management by unlocking the potential of big data. The project has identified critical evidence gaps in prostate cancer care, via a detailed prioritization exercise including all key stakeholders. By standardizing and integrating existing high-quality and multidisciplinary data sources from patients with prostate cancer across different stages of the disease, the resulting big data will be assembled into a single innovative data platform for research. Based on a unique set of methodologies, PIONEER aims to advance the field of prostate cancer care with a particular focus on improving prostate-cancer-related outcomes, health system efficiency by streamlining patient management, and the quality of health and social care delivered to all men with prostate cancer and their families worldwide. Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. In this Perspectives article, the authors introduce the PIONEER project and describe its aims and plans for ultimately improving prostate cancer care through the use of big data.
Introducing PIONEER: a project to harness big data in prostate cancer research
M. Omar, M. Roobol, M. Ribal, T. Abbott, P. Agapow, S. Araujo, A. Asiimwe, C. Auffray, I. Balaur, K. Beyer, C. Bernini, A. Bjartell, A. Briganti, J. Butler-Ransohoff, R. Campi, M. Cavelaars, B. De Meulder, Z. Devecseri, M. Voss, K. Dimitropoulos, S. Evans-Axelsson, B. Franks, L. Fullwood, D. Horgan, E. Smith, A. Kiran, K. Kivinummi, M. Lambrecht, D. Lancet, P. Lindgren, S. MacLennan, M. Nogueira, F. Moen, M. Moinat, K. Papineni, C. Reich, K. Reiche, S. Rogiers, C. Sartini, K. van Bochove, F. van Diggelen, M. Van Hemelrijck, H. Van Poppel, J. Zong, J. N'Dow, E. Andersson, H. Arala, A. Auvinen, C. Bangma, D. Burke, A. Cardone, J. Casariego, G. Cuperus, S. Dabestani, F. Esperto, N. Fossati, A. Fridhammar, G. Gandaglia, D. Tandefelt, F. Horn, J. Huber, J. Hugosson, H. Huisman, A. Josefsson, O. Kilkku, M. Kreuz, M. Lardas, J. Lawson, F. Lefresne, S. Lejeune, E. Longden-Chapman, G. McVie, L. Moris, N. Mottet, T. Murtola, C. Nicholls, K. Pang, K. Pascoe, M. Picozzi, K. Plass, P. Pohjanjousi, M. Reaney, S. Remmers, P. Robinson, J. Schalken, M. Schravendeel, T. Seisen, A. Servan, K. Shiranov, R. Snijder, C. Steinbeisser, N. Taibi, K. Talala, D. Tilki, T. den Van Broeck, Z. Vassilev, O. Voima, E. Vradi, R. Waldeck, W. Weistra, P. Willemse, M. Wirth, R. Wolfinger, N. Kermani and T. Consortium
Nature Reviews Urology 2020;17:351-362.